Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Share-based Compensation: 2019-2024

Historic Share-based Compensation for Centessa Pharmaceuticals (CNTA) over the last 6 years, with Dec 2024 value amounting to $33.5 million.

  • Centessa Pharmaceuticals' Share-based Compensation fell 14.89% to $7.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.4 million, marking a year-over-year decrease of 3.96%. This contributed to the annual value of $33.5 million for FY2024, which is 14.13% up from last year.
  • Centessa Pharmaceuticals' Share-based Compensation amounted to $33.5 million in FY2024, which was up 14.13% from $29.4 million recorded in FY2023.
  • Centessa Pharmaceuticals' 5-year Share-based Compensation high stood at $33.5 million for FY2024, and its period low was $336,000 during FY2020.
  • Its 3-year average for Share-based Compensation is $29.3 million, with a median of $29.4 million in 2023.
  • Data for Centessa Pharmaceuticals' Share-based Compensation shows a peak YoY spiked of 4,319.94% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Centessa Pharmaceuticals' Share-based Compensation stood at $336,000 in 2020, then surged by 4,319.94% to $14.9 million in 2021, then spiked by 68.10% to $25.0 million in 2022, then rose by 17.73% to $29.4 million in 2023, then rose by 14.13% to $33.5 million in 2024.